Strides Pharma Science Limited - Laporan Laba Rugi (TTM)

Strides Pharma Science Limited
IN ˙ NSEI ˙ INE939A01011
₹ 890.50 ↑6.85 (0.78%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Strides Pharma Science Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 29,264 30,260 33,159 32,224 31,504 31,127 30,702 33,220 34,976 35,680 36,884 36,783 37,806 39,535 38,901 42,086 44,103 45,794 45,653 46,307
Change (%) 3.40 9.58 -2.82 -2.24 -1.19 -1.36 8.20 5.29 2.01 3.37 -0.27 2.78 4.57 -1.60 8.19 4.79 3.83 -0.31 1.43
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 11,951 12,846 14,214 13,796 14,844 15,350 16,136 16,248 17,986 17,650 17,580 15,402 17,024 17,561 19,109 16,760 19,251 19,740 21,285 21,229
Change (%) 7.49 10.65 -2.94 7.60 3.40 5.12 0.70 10.69 -1.87 -0.39 -12.39 10.53 3.16 8.81 -12.29 14.86 2.54 7.82 -0.26
% of Revenue 40.84 42.45 42.87 42.81 47.12 49.31 52.56 48.91 51.42 49.47 47.66 41.87 45.03 44.42 49.12 39.82 43.65 43.11 46.62 45.84
Gross Operating Profit 17,313 17,414 18,945 18,428 16,659 15,778 14,566 16,971 16,990 18,031 19,304 21,381 20,783 21,973 19,793 25,326 24,852 26,054 24,369 25,078
Change (%) 0.58 8.79 -2.73 -9.60 -5.29 -7.68 16.51 0.11 6.12 7.06 10.76 -2.80 5.73 -9.92 27.96 -1.87 4.84 -6.47 2.91
% of Revenue 59.16 57.55 57.13 57.19 52.88 50.69 47.44 51.09 48.58 50.53 52.34 58.13 54.97 55.58 50.88 60.18 56.35 56.89 53.38 54.16
SG&A 5,192 5,359 5,704 5,817 6,120 6,636 6,728 6,692 7,385 7,395 7,686 7,159 7,607 7,642 7,893 7,958 8,675 9,005 9,328 9,497
Change (%) 3.22 6.44 1.99 5.21 8.43 1.39 -0.54 10.35 0.14 3.93 -6.86 6.26 0.46 3.29 0.82 9.02 3.80 3.58 1.82
% of Revenue 17.74 17.71 17.20 18.05 19.43 21.32 21.91 20.15 21.11 20.73 20.84 19.46 20.12 19.33 20.29 18.91 19.67 19.66 20.43 20.51
R&D
Change (%)
% of Revenue
OpEx 25,317 26,617 28,876 30,140 30,963 32,219 33,076 34,643 35,538 34,784 35,444 33,841 34,729 35,592 35,292 36,247 37,419 38,355 39,560 39,957
Change (%) 5.14 8.49 4.38 2.73 4.06 2.66 4.74 2.58 -2.12 1.90 -4.52 2.62 2.49 -0.84 2.70 3.24 2.50 3.14 1.00
% of Revenue 86.51 87.96 87.09 93.53 98.28 103.51 107.73 104.28 101.61 97.49 96.10 92.00 91.86 90.03 90.72 86.12 84.85 83.76 86.65 86.29
Operating Income 3,948 3,643 4,282 2,084 541 -1,091 -2,373 -1,423 -562 896 1,439 2,942 3,078 3,942 3,609 5,840 6,684 7,439 6,093 6,350
Change (%) -7.72 17.55 -51.33 -74.06 -301.89 117.45 -40.03 -60.52 -259.50 60.64 104.37 4.63 28.09 -8.46 61.81 14.46 11.30 -18.10 4.22
% of Revenue 13.49 12.04 12.91 6.47 1.72 -3.51 -7.73 -4.28 -1.61 2.51 3.90 8.00 8.14 9.97 9.28 13.88 15.15 16.24 13.35 13.71
Interest Expense -1,328 -1,278 -1,244 -1,546 -1,356 -1,432 -1,457 -1,898 -1,829 -1,991 -2,176 -2,830 -2,504 -2,713 -2,385 -3,184 -2,803 -2,621 -2,074 -2,074
Change (%) -3.73 -2.70 24.28 -12.27 5.58 1.76 30.27 -3.65 8.85 9.29 30.07 -11.52 8.32 -12.07 33.50 -11.98 -6.47 -20.87 -0.00
% of Revenue -4.54 -4.22 -3.75 -4.80 -4.31 -4.60 -4.75 -5.71 -5.23 -5.58 -5.90 -7.69 -6.62 -6.86 -6.13 -7.57 -6.35 -5.72 -4.54 -4.48
Net Income 745 184 2,684 -403 -2,838 -4,433 -4,602 -3,909 -2,055 -1,639 -2,026 -739 -2,280 -983 -706 67 2,313 35,294 35,935 3,416
Change (%) -75.25 1,356.39 -115.02 603.90 56.20 3.80 -15.06 -47.42 -20.26 23.65 -63.55 208.74 -56.88 -28.19 -109.49 3,351.37 1,426.07 1.81 -90.49
% of Revenue 2.55 0.61 8.10 -1.25 -9.01 -14.24 -14.99 -11.77 -5.88 -4.59 -5.49 -2.01 -6.03 -2.49 -1.82 0.16 5.24 77.07 78.71 7.38

Source: Capital IQ

Other Listings
IN:532531
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista